Irritable bowel syndrome is not a lifelong diagnosis you must live with — it is a symptom cluster with a biological mechanism behind it. We identify whether dysbiosis, barrier defect, immune reactivity or methylation dysfunction is driving your symptoms. And treat it.
Karlavägen 89, Stockholm · IBS investigation without waiting time
Irritable bowel syndrome (IBS) is defined in standard medicine as recurrent abdominal pain at least one day per week over three months, with altered stool frequency or consistency, without organic explanation. It is an exclusion diagnosis — not a biological explanation.
The problem is that "without organic explanation" does not mean "without biological mechanism." It means the standard investigation did not find the cause. Gut dysbiosis, low-grade inflammation, intestinal barrier defect and delayed food immune reactivity are invisible on colonoscopy and standard blood tests.
MediBalans IBS investigation maps the mechanisms that standard medicine does not measure — and treats them with targeted interventions based on your individual biology.
IBS symptoms look identical but are driven by different biological mechanisms. Treatment must match the mechanism — not the symptom.
Imbalance in gut microbiome composition with overgrowth of pathogenic bacteria and deficiency of protective species. Drives chronic low-grade intestinal inflammation, disrupts gut motility and produces symptom-generating metabolites. Mapped with the Gut Microbiome & Barrier test.
Increased intestinal permeability ("leaky gut") where the intestinal epithelium's tight junctions break down. Enables translocation of bacterial products into circulation, activates systemic immunity and drives chronic inflammation. Measured via I-FABP and Zonulin.
Non-IgE-mediated immune activation against foods, additives and chemicals. The reaction occurs 2–72 hours after ingestion and is impossible to identify with standard IgE allergy tests or elimination diets. Mapped with ALCAT test (200+ substances).
Polymorphisms in MTHFR, MTR and related genes affect gut motility, serotonin synthesis in the gut and immune regulation. Methylation dysfunction is an underestimated factor in IBS with pronounced psychological component (IBS-D with anxiety, depression). Mapped with MethylDetox.
Meet Mario AI analyses your clinical presentation, symptom pattern and history. Determines which analyses are clinically indicated.
ALCAT immune reactivity, Gut Microbiome & Barrier (I-FABP, Zonulin), CMA intracellular nutrition and where indicated MethylDetox.
Meet Mario AI integrates results via the Global Constraint Rule — identifies the primary mechanism and sequences the treatment hierarchy.
Treatment protocol based on your biological profile. Follow-up with objective biomarkers confirming biological response.
Measures cellular immune reactivity against 200+ foods, additives and chemicals. Identifies delayed non-IgE-mediated reactivity driving chronic gut inflammation and IBS symptoms.
Maps gut microbiome composition and barrier integrity. I-FABP measures intestinal epithelial damage. Zonulin measures gut permeability. Identifies dysbiosis patterns and barrier defect.
55 intracellular nutritional markers including vitamins, minerals and antioxidants. Shows functional nutritional status determining whether biological processes have sufficient cofactors.
Maps methylation capacity and genetic polymorphisms affecting serotonin synthesis in the gut, immune regulation and detoxification capacity.
Read more about MethylDetox →The gut-brain axis. In IBS with pronounced stress component, HRV analysis maps the autonomic imbalance driving gut symptoms via the vagus nerve and enteric nervous system.
Read more about HRV analysis →GI Effects (advanced gut diagnostics), SIBO test (small intestinal bacterial overgrowth) and NutrEval (metabolic analysis) via MediBalans as official Swedish distributor.
IBS is not a diagnosis with a single cause — it is a symptom cluster with several possible biological mechanisms: gut dysbiosis, intestinal barrier defect, delayed food immune reactivity, SIBO, methylation dysfunction or combinations. Standard medicine's IBS diagnosis does not identify which mechanism is driving symptoms in the individual patient. MediBalans maps the specific mechanism.
Dysbiosis is an imbalance in gut microbiome composition with overgrowth of pathogenic bacteria and deficiency of protective species. Dysbiosis drives chronic low-grade intestinal inflammation, disrupts gut motility, breaks down barrier integrity and produces symptom-generating metabolites. It is a common underlying mechanism in IBS rarely identified in standard investigation.
Yes — but rarely via classical food allergy. IBS symptoms are often triggered by delayed immune reactivity — a non-IgE-mediated reaction activated 2–72 hours after ingestion that is impossible to identify without ALCAT testing. Standard elimination diets and FODMAP protocols do not address the underlying immune mechanism and often produce inconsistent results for precisely this reason.
Standard care IBS investigation excludes organic disease and then gives a symptom diagnosis without identifying biological mechanism. MediBalans maps immune reactivity (ALCAT), gut microbiome and barrier integrity (I-FABP, Zonulin), intracellular nutritional status (CMA) and where indicated methylation capacity (MethylDetox). Meet Mario AI integrates results via the Global Constraint Rule and identifies the primary mechanism.
No referral is required. MediBalans accepts patients directly. Book an initial consultation at Karlavägen 89 in Stockholm.
Book an initial consultation. We map the mechanism behind your symptoms and build a treatment protocol based on your individual biology.